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Pathologic complete response (pCR) after NC has been consistently associated with improved outcomes. Residual DCIS after
NC does not portray worse prognosis compared to complete eradication of all disease but has clinical implications regarding
surgical management. We report a case of pCR of DCIS associated with invasive carcinoma in an HER-2 + tumor after NC plus
trastuzumab despite persistence of malignant-appearing microcalciﬁcations mammographically. A 41-year-old Caucasian female
presentedwitha4×4cmmassintherightbreastanda2.5cmrightaxillarynode.Mammogramshoweda2.5cmmassanda12cm
area of linear pleomorphic, suspicious calciﬁcations in the upper part of the breast. Core biopsy revealed invasive ductal carcinoma
and DCIS associated with calciﬁcations (ER 85%, PR 6%, Her2neu 3+ by IHC). Axillary node FNA was positive for malignancy.
The patient received doxorubicin/cyclophosphamide (AC) → paclitaxel plus T with complete clinical and radiologic response
but no signiﬁcant change in the microcalciﬁcations. Final pathology showed no residual invasive carcinoma or DCIS despite
the presence of numerous ducts with microcalciﬁcations. Documented eradication of DCIS has not been reported following NC
when malignant-appearing calciﬁcations persist and this observation may have important clinical implications regarding surgical
management.
1.CaseReport
A 41-year-old female presented with a three-week history of
palpable mass of the right breast and a three-day history of
a palpable lump in the right axilla. Her past medical history
was unremarkable except for history of thyroid insuﬃciency
(on thyroid replacement) and a benign cyst removal from
the left breast at the age of 14. She had menarche at the
age of 13 and has one child (delivered at the age of 31). She
is currently premenopausal and on birth control pills. Her
family history is remarkable for breast cancer in two paternal
cousins (diagnosed in their 40’s), and for prostate cancer in
her father (died at the age of 65).
On examination, there was a 4 × 4cm mass in the upper
part of the right breast not ﬁxed to underlying pectoralis
muscle or overlying skin. There was also an enlarged right
axillary node measuring approximately 2.5cm in diameter,
which was not ﬁxed to surrounding structures. Digital
mammography revealed a new 2.5cm irregular solid mass
at the 12 o’clock position of the right breast, which was
highly suggestive of malignancy, and a 12cm area of linear
pleomorphic calciﬁcations occupying most of the upper part
of the right breast (Figures 1(a) and 1(c)). A targeted right
breast ultrasound demonstrated an irregular solid, hypoe-
choic mass measuring 2.5cm in diameter, and ultrasound of

















Figure 1: Comparison of mammographic studies before and after neoadjuvant chemotherapy. (a) Right MLO view prior to neoadjuvant
chemotherapy. The blue arrow indicates the mass with surrounding microcalciﬁcations. The yellow arrows indicate additional malignant-
appearing microcalciﬁcations occupying the upper part of the right breast. (b) Right MLO view after neoadjuvant chemotherapy. The
blue arrow shows resolution of the mass but persistence of surrounding microcalciﬁcations. The yellow arrows show persistence of the
additional, extensive microcalciﬁcations. (c) Right CC view prior to neoadjuvant chemotherapy. The yellow arrows indicate the areas of
microcalciﬁcations.Thebluearrowindicatesthebreastmass.(d)RightCCviewafterneoadjuvantchemotherapy.Theyellowarrowsindicate
the areas of persistent microcalciﬁcations. The blue arrow shows complete resolution of the breast mass.
enlarged lymph node measuring 1.7cm in diameter. The
patient underwent an ultrasound-guided core biopsy of the
right breast mass and an FNA of the axillary node. The
core biopsy demonstrated invasive, moderately to poorly
diﬀerentiated ductal adenocarcinoma, extensively involving
both core biopsy fragments (Figure 2(a)). In addition, grade
3 DCIS, solid and clinging types, with comedonecrosis, and
focal associated microcalciﬁcations were seen (Figure 2(b)).
Lymphovascular invasion was present. Immunohistochemi-
cal staining of the tumor showed strongly positive estrogen
receptor (ER) at 85%, weakly positive progesterone receptor
(PR) at 6%, and positive HER2neu overexpression (3+). The
right axillary lymph node cytology conﬁrmed the presence
of metastatic adenocarcinoma consistent with breast origin.
A bilateral breast MRI revealed a 2.7cm irregular mass in the





Figure 2: Pathologic ﬁndings from core needle biopsy before neoadjuvant chemotherapy. (a) H & E stain showing high-grade invasive







Figure 3: Comparison of bilateral breast MRI studies performed before and after neoadjuvant chemotherapy. (a) Doppler ﬂow MRI before
neoadjuvant chemotherapy. Yellow arrow points to the 2.7cm irregular mass in the right breast. (b) Doppler ﬂow MRI after neoadjuvant
chemotherapy shows complete radiologic response. Yellow arrow points to area where the mass was located prior to treatment.
of delayed washout type enhancement were also identiﬁed,
predominantly involving the upper inner quadrant and the
region central to the nipple in the posterior depth. These foci
correlated with the pleomorphic calciﬁcations seen on the
comparison mammogram and were thought to most likely
represent multifocal disease. In the right axilla, there was a
2.6cm pathologically enlarged lymph node, likely metastatic
(Figure 4(a)). Metastatic workup including CT scan of the
chest/abdomen/pelvis and bone scan was negative.
The decision was made to proceed with neoadjuvant
chemotherapy plus trastuzumab. The patient received four
cycles of doxorubicin and cyclophosphamide (AC) followed
by 12 cycles of weekly paclitaxel plus trastuzumab. After the
ﬁrst cycle of AC, there was a noticeable decrease in the size of
thebreastmass,andtheaxillarynodewasnolongerpalpable.
The patient had complete clinical response following the
four cycles of AC and maintained it while on paclitaxel plus
trastuzumab. During this time, she was also referred to the
Genetics Clinic for evaluation given her family history of
breast and prostate cancer. She was found to be negative for
BRCA-1andBRCA-2mutationsincludingtheBRACanalysis
rearrangement test (BART).
Prior to surgery, a diagnostic mammogram of the right
breast was obtained, showing no signiﬁcant change in the
diﬀuse pleomorphic calciﬁcations, but complete resolution
of the breast and axillary masses (Figures 1(b) and 1(d)). An
MRI also showed complete radiologic response to treatment
(Figures 3(b) and 4(b)). There was also no sonographic evi-
dence of malignancy, and all axillary lymph nodes appeared
benign.
Given the complete clinical response but persistence of







Figure 4: Comparison of bilateral MRI of the right axilla performed before and after neoadjuvant chemotherapy. (a) Doppler ﬂow MRI
before neoadjuvant chemotherapy. Yellow arrow points to a 2.6cm pathologically enlarged right axillary lymph node. (b) Doppler ﬂow MRI






Figure 5: Pathologic ﬁndings from the surgical specimen obtained following neoadjuvant chemotherapy. Both pictures show no evidence
of residual malignancy indicating a pathologic complete response. Black arrows point to benign appearing ducts with foamy macrophages,
ﬁbrous reactive tissue, and residual intraductal microcalciﬁcations without evidence of DCIS.
throughout the upper part of the breast, indicating extensive
intraductal component, a total mastectomy was recom-
mended. Because of her family and personal history indicat-
ingpossiblegeneticpredisposition(albeitnotBRCArelated),
the patient opted for contralateral prophylactic mastectomy.
Given the complete resolution of the right axillary node, she
was entered into the ACOSOG Z071 trial evaluating sentinel
node biopsy followed by completion axillary dissection in
patients receiving neoadjuvant chemotherapy. Surgical treat-
ment included bilateral skin-sparring mastectomy with right
SNB and right completion axillary dissection. Bilateral sub-
muscular tissue expanders were used for immediate recon-
struction. Pathology demonstrated three negative sentinel
lymph nodes and 17 negative nonsentinel lymph nodes. The
biopsy cavity, 2.0 × 1.5c m ,s h o w e dn oe v i d e n c eo fr e s i d u a l
carcinoma or DCIS. The specimen contained numerous
residual microcalciﬁcations but no malignancy (Figures 5(a)
and 5(b)). The patient was considered to have achieved a
pathologic complete response (pCR).
The patient did well postoperatively although she had to
undergominorrevisionoftherightmastectomyﬂapbecause
of a small area of necrosis. Trastuzumab for the remaining of
one year and tamoxifen therapy are planned. The need for
postoperative radiation therapytothe rightchestwalland/or
regional nodal basins was discussed at the Multidisciplinary
Tumor Board, given her original presentation with a positive
axillary node. There were divergent opinions regarding the
need for XRT given the complete pathologic response.Case Reports in Surgery 5
Ultimately, the patient decided not to receive postoperative
radiation therapy.
2. Discussion
Neoadjuvant chemotherapy has become the standard of
care for patients with locally advanced breast cancer and
is currently considered a reasonable alternative to adju-
vant chemotherapy for patients with large operable disease
[1]. Pathologic complete response (pCR) after neoadju-
vant chemotherapy has been consistently associated with
improved outcomes [2–5]. The most common deﬁnition of
pCR includes absence of invasive carcinoma in the breast
and axillary nodes. Residual DCIS after NC does not portray
worse prognosis compared to complete eradication of all
disease [6, 7]. However, even if presence of residual DCIS
does not aﬀect long-term outcome, it has clinical implica-
tions regarding the surgical management of the patient and
may at times lead to the need for more extensive resections,
includingtheneedformastectomydespiteexcellentresponse
to neoadjuvant chemotherapy.
To our knowledge, complete eradication of docu-
mented extensive intraductal component with neoadjuvant
chemotherapy has not been reported if there are persis-
tent malignant-appearing microcalciﬁcations at the time of
surgery. Whether the intraductal component of a tumor
can be eradicated with neoadjuvant chemotherapy is con-
troversial [8, 9]. Matsuo et al. evaluated the concordance in
pathologic response to neoadjuvant chemotherapy between
the invasive and the noninvasive components of primary
breast carcinomas in 100 patients receiving neoadjuvant
chemotherapy [8]. They found a strong correlation in
pathologic complete response between the invasive and non-
invasive components (P<0.001). However, in that paper,
they did not comment on the persistence or eradication of
associated microcalciﬁcations. On the other hand, Wu et al.
[9] evaluated 25 patients with locally advanced breast cancer
who received neoadjuvant chemotherapy with special atten-
tiontotheproportionofintraductalcomponent.Theyfound
that although neoadjuvant chemotherapy had a favorable
eﬀect on tumor reduction, its eﬀectiveness varied depending
on the predominance of the intraductal component. Cases
with high proportion of intraductal component had lower
response to neoadjuvant chemotherapy, and a large number
of malignant cells remained in the mammary ducts of such
cases. In addition, these residual cancer cells maintained
proliferative activity. Based on their ﬁndings, they concluded
that the intraductal component is poorly responsive to
neoadjuvant chemotherapy.
Since the presence of malignant-appearing microcalci-
ﬁcations is usually a good surrogate for the presence of
extensive intraductal component associated with invasive
breast cancer, it is of interest to examine the fate of such
microcalciﬁcations following neoadjuvant chemotherapy.
Several reports exist in the literature on the eﬀect of
neoadjuvant chemotherapy on microcalciﬁcations [10–16].
The majority of these reports demonstrate no changes in the
malignant-appearing microcalciﬁcations with the adminis-
tration of neoadjuvant chemotherapy. Junkermann and von
Fournier observed no regression of microcalciﬁcations fol-
lowing administration of neoadjuvant chemotherapy, even
when the invasive tumor did show regression, hinting to
the presence of noninvasive residual tumor [13]. Ferranti
et al. [14] analyzed the morphology, number, and extent of
the microcalciﬁcations and assessed their value as reliable
parameters of cancer response to primary chemotherapy.
Theyfoundthatincreasedvisibilityofthemicrocalciﬁcations
after chemotherapy was due to a reduction in both edema
and lesion opacity. They concluded that microcalciﬁcations
are a useful parameter for diagnosis, but they alone are less
important when evaluating response to primary chemother-
apy. In some reports, microcalciﬁcations are found to
develop during neoadjuvant chemotherapy. Fadul et al.
[16] described a patient diagnosed with stage III breast
cancerandnomicrocalciﬁcationspriortoneoadjuvanttreat-
ment, who developed microcalciﬁcations after treatment.
These microcalciﬁcations were histologically associated with
both intraductal and invasive carcinomas. In contrary,
some studies have reported a decrease in the number
of microcalciﬁcations with neoadjuvant chemotherapy or
even complete disappearance. Adwani et al. [12]r e p o r t e d
a case of complete resolution of all malignant-appearing
microcalciﬁcations after neoadjuvant chemotherapy, but
Noguera Tajadura et al. found that microcalciﬁcations
evolve unpredictably and independently of tumor response
to neoadjuvant chemotherapy [17]. Moskovic et al. [11]
hypothesized that residual microcalciﬁcations after neoadju-
vant chemotherapy could be explained by the calciﬁcation
of necrotic material remaining from the tumor or even
fat necrosis or hematoma formation after biopsy. A study
looking at the mammographic changes of 95 breast cancer
patients after neoadjuvant chemotherapy found that patients
with microcalciﬁcations did not have complete response,
and the prediction of pathologic outcome was not possible
using mammograms [18]. Similarly, Segal et al. reported
that microcalciﬁcations may decrease in number, but rarely
disappeared, and their persistence was usually associated
with residual intraductal carcinoma [10].
One can question whether our observations represent
true eradication of DCIS or merely the result of inadequate
pathologic sampling of the tumor bed area. In support of a
complete eradication of DCIS is the identiﬁcation of several
ducts that contained microcalciﬁcations associated with
high-grade DCIS on the original core biopsy specimen and
similarly the identiﬁcation of several ducts with microcalci-
ﬁcations that appeared normal on ﬁnal pathology following
neoadjuvant chemotherapy (Figures 5(a) and 5(b)).
Trastuzumab has been shown to be an eﬀective anti-
HER2 targeted therapy when used in the adjuvant setting for
invasive breast cancer. Clearly, the addition of trastuzumab
to chemotherapy in patients with HER-2-positive invasive
carcinoma has been associated with considerable increase
in pCR rates. It has been proposed that trastuzumab may
downstage DCIS and possibly prevent transition from DCIS
to invasive breast cancer [19]. Because DCIS is earlier in
the carcinogenic pathway, it is more likely to depend on
a single pathway rather than alternate escape pathways.
Currently, new studies evaluating adjuvant and neoadjuvant6 Case Reports in Surgery
trastuzumabanditseﬀectonHER2-overexpressingDCISare
enrolling (NSABP B-43, MD Anderson DCIS neoadjuvant
trial) [19].
We believe that this is the ﬁrst report of documented
complete eradication of the noninvasive component despite
the persistence of malignant-appearing microcalciﬁcations
in a patient receiving neoadjuvant chemotherapy plus
trastuzumab. Whether the addition of trastuzumab to
chemotherapy contributed to this result is unknown at
present.
Our observation, if reproduced by others, particularly
in clinical trials comparing neoadjuvant chemotherapy
versus neoadjuvant chemotherapy plus trastuzumab, may
have clinical implications regarding surgical management of
patients with HER-2 neu-positive breast cancer who have
excellent clinical and radiologic response to neoadjuvant
chemotherapy plus trastuzumab but have residual microcal-
ciﬁcations. In such cases, core biopsy conﬁrmation of the
true nature of residual microcalciﬁcations may be needed
before proceeding with more extensive surgical resection
based on the extent of microcalciﬁcations.
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